Tanja Fehm
0000-0002-4926-0108
Publication & Citation Trends
Most Cited Works
Publications
1,951 total
Trastuzumab deruxtecan versus treatment of physician's choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial PDF
Cited by 332
OpenAlex
Lysosomal acid lipase-activity as a novel target to efficiently address triple-negative breast cancer high malignancy OA
Cited by 1
Semantic Scholar
Primary hepatic metastatic epitheloid trophoblastic tumor of the uterus treated with multimodal therapy including pembrolizumab and thermoablation. Case report of an extremely rare disease and review of the literature OA
Cited by 3
Semantic Scholar
Pooled Analysis of the Prognostic Relevance of Circulating Tumor Cells in Primary Breast Cancer PDF
Cited by 362
OpenAlex
Bilateral diffuse pseudoangiomatous stromal hyperplasia (PASH) causing gigantomastia in a 33-year-old pregnant woman: case report OA
Cited by 0
Semantic Scholar
Clinical validity of circulating tumour cells in patients with metastatic breast cancer: a pooled analysis of individual patient data
Cited by 833
OpenAlex
Research Topics
Breast Cancer Treatment Studies
(456)
Cancer Cells and Metastasis
(416)
Cancer Genomics and Diagnostics
(335)
Advanced Breast Cancer Therapies
(316)
HER2/EGFR in Cancer Research
(293)
Frequent Co-Authors
Affiliations
University of Stuttgart
Goethe University Frankfurt
Australian National University
Oslo University Hospital
Merck & Co., Inc., Rahway, NJ, USA (United States)